Summit Therapeutics (SMMT) Equity Average (2020 - 2026)
Summit Therapeutics filings provide 7 years of Equity Average readings, the most recent being $602.4 million for Q1 2026.
- Quarterly Equity Average rose 64.35% to $602.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $602.4 million through Mar 2026, up 64.35% year-over-year, with the annual reading at $523.8 million for FY2025, 124.6% up from the prior year.
- Equity Average hit $602.4 million in Q1 2026 for Summit Therapeutics, up from $425.6 million in the prior quarter.
- Across five years, Equity Average topped out at $602.4 million in Q1 2026 and bottomed at $57.9 million in Q2 2022.
- Average Equity Average over 5 years is $214.2 million, with a median of $130.0 million recorded in 2022.
- The largest annual shift saw Equity Average crashed 53.14% in 2024 before it soared 501.37% in 2025.
- Summit Therapeutics' Equity Average stood at $130.0 million in 2022, then plummeted by 31.87% to $88.5 million in 2023, then surged by 366.86% to $413.3 million in 2024, then increased by 2.96% to $425.6 million in 2025, then surged by 41.55% to $602.4 million in 2026.
- Per Business Quant, the three most recent readings for SMMT's Equity Average are $602.4 million (Q1 2026), $425.6 million (Q4 2025), and $225.9 million (Q3 2025).